Dr. Tom Hawes
PARTNER, CLINICAL
Dr. Tom Hawes joined Sandbox in 2008 and is a Partner at Sandbox Industries and a Managing Director at the Blue Venture Fund. Tom is a member of the Board of Directors of Humata Health, Octave Bioscience, and Upward Health. He also serves as a Board Observer of Onc.ai and Ultromics. Dr. Hawes previously served as a Board Member of Phreesia (NYSE: PHR), PatientCo (acquired by WayStar), AbleTo (acquired by Optum), OncoHealth (acquired by Arsenal Capital Partners and McKesson), Healthify (acquired by Wellsky), HeartFlow, InVivoLink (acquired by HCA), Nexidia (acquired by NICE), and Verata Health (acquired by Olive.Ai), First Dollar (acquired by Inspira Financial), and as a Board Observer of Thrive Earlier Detection (NASDAQ: EXAS).
Prior to joining Sandbox, Dr. Hawes matched at Yale School of Medicine for residency. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and New York Medical College’s Cardiothoracic Surgery Department.
Dr. Hawes holds an MD from New York Medical College, an MBA from Harvard Business School, and a BA from Brigham Young University. He is also a Kauffman Fellow. He lives in Austin, Texas and enjoys time with his family and community.
PARTNER, CLINICAL
Dr. Tom Hawes joined Sandbox in 2008 and is a Partner at Sandbox Industries and a Managing Director at the Blue Venture Fund. Tom is a member of the Board of Directors of Humata Health, Octave Bioscience, and Upward Health. He also serves as a Board Observer of Onc.ai and Ultromics. Dr. Hawes previously served as a Board Member of Phreesia (NYSE: PHR), PatientCo (acquired by WayStar), AbleTo (acquired by Optum), OncoHealth (acquired by Arsenal Capital Partners and McKesson), Healthify (acquired by Wellsky), HeartFlow, InVivoLink (acquired by HCA), Nexidia (acquired by NICE), and Verata Health (acquired by Olive.Ai), First Dollar (acquired by Inspira Financial), and as a Board Observer of Thrive Earlier Detection (NASDAQ: EXAS).
Prior to joining Sandbox, Dr. Hawes matched at Yale School of Medicine for residency. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and New York Medical College’s Cardiothoracic Surgery Department.
Dr. Hawes holds an MD from New York Medical College, an MBA from Harvard Business School, and a BA from Brigham Young University. He is also a Kauffman Fellow. He lives in Austin, Texas and enjoys time with his family and community.
PARTNER, CLINICAL
Dr. Tom Hawes joined Sandbox in 2008 and is a Partner at Sandbox Industries and a Managing Director at the Blue Venture Fund. Tom is a member of the Board of Directors of Humata Health, Octave Bioscience, and Upward Health. He also serves as a Board Observer of Onc.ai and Ultromics. Dr. Hawes previously served as a Board Member of Phreesia (NYSE: PHR), PatientCo (acquired by WayStar), AbleTo (acquired by Optum), OncoHealth (acquired by Arsenal Capital Partners and McKesson), Healthify (acquired by Wellsky), HeartFlow, InVivoLink (acquired by HCA), Nexidia (acquired by NICE), and Verata Health (acquired by Olive.Ai), First Dollar (acquired by Inspira Financial), and as a Board Observer of Thrive Earlier Detection (NASDAQ: EXAS).
Prior to joining Sandbox, Dr. Hawes matched at Yale School of Medicine for residency. During his medical training, he worked on clinical studies at the ISK Institute for Orthopedics and Sports Medicine and on outcomes research at the National Cancer Institute and New York Medical College’s Cardiothoracic Surgery Department.
Dr. Hawes holds an MD from New York Medical College, an MBA from Harvard Business School, and a BA from Brigham Young University. He is also a Kauffman Fellow. He lives in Austin, Texas and enjoys time with his family and community.